FDA sends warning letter to Novo Nordisk over failure to report deaths, adverse side effects of GLP-1s

The U.S. Food and Drug Administration (FDA) has issued a informing to Novo Nordisk implicit its alleged nonaccomplishment to study adverse broadside effects, including death, successful patients who took its GLP-1 medications, popularly known arsenic Ozempic and Wegovy. The FDA wrote successful a March 5 missive that it observed “serious violations” of reporting requirements during…